Q5 net sales rose 18% year-over-year to SEK 512,055, with net loss improving to SEK -1,109,318. The company strengthened its team, secured a new oncology patent, and expects short-term revenue impact from a lost contract but anticipates growth from China market entry.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.